Hypothesis

A single psilocybin dose triggers a sleep‑dependent glymphatic surge that tags newly formed dendritic spines for long‑term retention, thereby converting acute default mode network (DMN) disruption into enduring structural remodeling and antidepressant efficacy.

Mechanistic Rationale

Psilocybin acutely increases global connectivity and decreases intra‑DMN coupling [1], an effect that is activity‑dependent and persists for weeks [2]. Concurrently, it elevates BDNF expression [4] and drives ~10% increases in dendritic spine density and head size in mouse medial frontal cortex that last at least one month [3]. Recent work shows that the glymphatic system, most active during slow‑wave sleep, clears extracellular metabolites and distributes neurotrophic factors throughout the parenchyma [glymphatic review]. We propose that psilocybin‑induced heightened neuronal activity during the post‑dose window amplifies glymphatic influx, which in turn delivers BDNF and other plasticity‑promoting molecules to active synapses. This creates a synaptic tagging–capture scenario: spines formed during the acute psychedelic state are ‘tagged’ by activity‑dependent signaling, and the glymphatic‑borne BDNF serves as the capture factor that stabilizes these spines, preventing their elimination during normal turnover.

If this coupling occurs, the structural changes that underlie DMN‑hippocampus decoupling [2] become resistant to regression, explaining the durability of clinical effects up to six months [5].

Predictions and Experimental Design

1. Glymphatic inhibition blocks long‑term DMN remodeling. In mice, administer psilocybin then either (a) genetically suppress AQP4‑dependent glymphatic flow or (b) pharmacologically impair slow‑wave sleep with acetazolamide. Measure functional DMN connectivity via resting‑state fMRI and dendritic spine density in medial frontal cortex at 1 day, 1 week, and 4 weeks post‑dose. Prediction: glymphatic impairment will abolish the week‑to‑month increase in spine density and prevent persistent DMN‑hippocampus decoupling, while acute effects (first 24 h) remain intact.
2. BDNF‑glymphatic interaction is necessary for spine capture. Use a BDNF‑trkB signaling blocker (ANA‑12) delivered intracerebroventricularly during the sleep period following psilocybin. Prediction: spine density gains will be prevented despite normal glymphatic flow, indicating that BDNF delivery via the glymphatic route is essential for capture.
3. Human biomarker correlation. In a double‑blind psilocybin trial, acquire overnight CSF glymphatic influx metrics (via intrathecal contrast‑enhanced MRI) and serum BDNF levels the morning after dosing. Correlate these acute metrics with changes in DMN functional connectivity at 2 weeks and depressive symptom improvement (MADRS) at 1 month and 6 months. Prediction: higher glymphatic influx and BDNF surge will predict greater long‑term DMN remodeling and clinical response.

Potential Implications

Confirming this hypothesis would reposition sleep quality as a critical modulator of psychedelic therapeutics, suggesting that adjunctive sleep enhancement (e.g., auditory slow‑wave stimulation) could amplify and prolong benefits. Conversely, it identifies glymphatic dysfunction as a potential biomarker for non‑response, guiding patient selection. Ultimately, it offers a concrete, falsifiable mechanistic bridge between acute network pharmacology, synaptic plasticity, and sustained clinical outcomes.